These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21470022)

  • 41. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.
    Mata-Marín JA; Mata-Marín LA; Arroyo-Anduiza CI; Huerta-García G; Sandoval-Ramirez JL; Manjarrez-Tellez B; Gaytán-Martínez JE
    Hepatogastroenterology; 2014; 61(133):1187-91. PubMed ID: 25436280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
    Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
    J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
    HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
    Polk C; Chan-Tack KM; Kopack AM; Amoroso A
    AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
    [No Abstract]   [Full Text] [Related]  

  • 45. Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
    Karim SS; Karim QA
    Lancet; 2012 Jun; 379(9831):2047-8. PubMed ID: 22608193
    [No Abstract]   [Full Text] [Related]  

  • 46. [HIV infected women with intense bone and muscular pain and general weakness].
    Pérez-Rivera AÁ; Sáez P; León E; Lozano de León-Naranjo F
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):308-10. PubMed ID: 21334782
    [No Abstract]   [Full Text] [Related]  

  • 47. Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
    Allavena C; Bach-Ngohou K; Billaud E; Sécher S; Dejoie T; Reliquet V; Fakhouri F; Raffi F
    J Antimicrob Chemother; 2013 Dec; 68(12):2866-70. PubMed ID: 23818285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiretroviral preexposure prophylaxis for preventing HIV infection in high-risk individuals.
    Saguil A
    Am Fam Physician; 2013 Aug; 88(3):172-3. PubMed ID: 23939695
    [No Abstract]   [Full Text] [Related]  

  • 49. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 50. Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.
    Nichols BE; Boucher CA; van Dijk JH; Thuma PE; Nouwen JL; Baltussen R; van de Wijgert J; Sloot PM; van de Vijver DA
    PLoS One; 2013; 8(3):e59549. PubMed ID: 23527217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
    Laessig KA; Lewis LL; Hammerstrom TS
    N Engl J Med; 2006 Jun; 354(23):2506-8; author reply 2506-8. PubMed ID: 16760455
    [No Abstract]   [Full Text] [Related]  

  • 52. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
    van de Vijver DA; Nichols BE; Abbas UL; Boucher CA; Cambiano V; Eaton JW; Glaubius R; Lythgoe K; Mellors J; Phillips A; Sigaloff KC; Hallett TB
    AIDS; 2013 Nov; 27(18):2943-51. PubMed ID: 23939237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.
    Periard D; Yerly P; Hayoz D; Mazzolai L; Widmeier A; Cavassini M
    Antivir Ther; 2009; 14(6):865-7. PubMed ID: 19812450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA
    J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
    Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
    PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Women testing tenofovir for HIV prevention.
    AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747428
    [No Abstract]   [Full Text] [Related]  

  • 58. Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?
    Estebanez M; Stella-Ascariz N; Ruiz-Carrascoso G; Zamora FX; García-Bujalance S; Bernardino JI; Pérez-Valero I; Martin-Quirós A; Mingorance J; Arribas JR
    AIDS; 2013 Jan; 27(1):141-4. PubMed ID: 22914581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emtricitabine + tenofovir to prevent HIV transmission. More evaluation needed.
    Prescrire Int; 2013 Jul; 22(140):178-81. PubMed ID: 23951592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case report of cytomegalovirus retinitis in an HIV-positive patient with a CD4-count nadir of 254 cells per μl.
    Ang BC; Teoh SC
    Eye (Lond); 2012 Aug; 26(8):1153-4. PubMed ID: 22595905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.